Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

Cited by (531)

Items 101–200 of 531

1. Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells
   Rein Verbeke, Ine Lentacker, Karine Breckpot, J. Janssens, Serge Van Calenbergh, Stefaan C. De Smedt, Heleen Dewitte · 2019 · ACS Nano
2. Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice
   Katherine L. Mallory, Justin A. Taylor, Xiaoyan Zou, Ishita N. Waghela, Cosette G. Schneider, Michael Q. Sibilo, Neeraja M. Punde, Leah Perazzo, Tatyana Savransky, Martha Sedegah et al. · 2021 · npj Vaccines
3. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease
   Matthew Pine, Gunjan Arora, Thomas M. Hart, Emily Bettini, Brian T. Gaudette, Hiromi Muramatsu, István Tombácz, Taku Kambayashi, Ying K. Tam, Dustin Brisson et al. · 2023 · Molecular Therapy
4. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
   Meagan McMahon, George O’Dell, Jessica Tan, András Sárközy, Máté Vadovics, Juan Manuel Carreño, Eduard Puente‐Massaguer, Hiromi Muramatsu, Csaba Bajusz, Willemijn F. Rijnink et al. · 2022 · Proceedings of the National Academy of Sciences
5. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice
   Zekun Mu, Kevin J. Wiehe, Kevin O. Saunders, Rory C. Henderson, Derek W. Cain, Robert Parks, Diana Martik, Katayoun Mansouri, Robert J. Edwards, Amanda Newman et al. · 2022 · Cell Reports
6. Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates
   Yuta Suzuki, Takayuki Miyazaki, Hiroki Muto, Kenji Kubara, Yohei Mukai, Ryuji Watari, Shinya Sato, Keita Kondo, Shin‐ichi Tsukumo, Koji Yasutomo et al. · 2022 · Molecular Therapy — Nucleic Acids
7. HIV mRNA Vaccines—Progress and Future Paths
   Zekun Mu, Barton F. Haynes, Derek W. Cain · 2021 · Vaccines
8. Developments in Vaccination for Herpes Simplex Virus
   Rohini Krishnan, Patrick M. Stuart · 2021 · Frontiers in Microbiology
9. Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery
   Magdalena M. Żak, Lior Zangi · 2021 · Pharmaceutics
10. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-β at the injection site
    Seongryong Kim, Ji Hyang Jeon, Myeonghwan Kim, Yeji Lee, Yun-Ho Hwang, Myungsun Park, C. Han Li, Taeyoung Lee, Jung-Ah Lee, You‐Me Kim et al. · 2024 · Nature Communications
11. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung
    Matthew Gagné, Kizzmekia S. Corbett, Barbara J. Flynn, Kathryn E. Foulds, Danielle A. Wagner, Shayne F. Andrew, John-Paul M. Todd, Christopher Cole Honeycutt, Lauren McCormick, Saule T. Nurmukhambetova et al. · 2021 · Cell
12. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
    Drew Weissman, Mohamad‐Gabriel Alameh, Thushan I. de Silva, Paul Collini, Hailey R. Hornsby, Rebecca L. Brown, Celia C. LaBranche, Robert J. Edwards, Laura L. Sutherland, Sampa Santra et al. · 2020 · medRxiv
13. Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers
    Si’Ana A. Coggins, Eric D. Laing, Cara H. Olsen, Emilie Goguet, Matthew S. Moser, Belinda M Jackson-Thompson, Emily C Samuels, Simon D. Pollett, David R. Tribble, Julian Davies et al. · 2021 · Open Forum Infectious Diseases
14. Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design
    Bruna Clemente, Maxime Denis, Camila Pedroso Silveira, Francesca Schiavetti, Michela Brazzoli, Daniela Stranges · 2023 · Frontiers in Immunology
15. CD4+ T cells promote humoral immunity and viral control during Zika virus infection
    Annie Elong Ngono, Matthew Perry Young, Maximilian Bunz, Zhi-Gang Xu, Sararat Hattakam, Edward A. Vizcarra, José Ángel Regla-Nava, William Weihao Tang, Montarop Yamabhai, Jinsheng Wen et al. · 2019 · PLoS Pathogens
16. Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
    Xiubao Ren, Zhenzhen Hui, Jiali Zhang, Yulin Ren, XIAOLING LI, Cihui Yan, Tao Wang, Wenwen Yu, Tao Wang, Shanshan Xiao et al. · 2022 · Cell Death and Disease
17. COVID-19 and children
    Carl A. Pierce, Kevan C. Herold, Betsy C. Herold, Janet S. Chou, Adrienne G. Randolph, Binita Kane, Sammie McFarland, Deepti Gurdasani, Christina Pagel, Peter Jay Hotez et al. · 2022 · Science
18. Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic
    Ziqi Wang, Kai Cui, Ulrich Costabel, Xiaoju Zhang · 2022 · Exploration
19. Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: A combined in vitro and preclinical perspective
    Burcu Binici, Zahra Rattray, Assaf Zinger, Yvonne Perrie · 2024 · Journal of Controlled Release
20. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection
    Kevin P. Egan, Lauren M. Hook, Alexis M. Naughton, Norbert Pardi, Sita Awasthi, Gary H. Cohen, Drew Weissman, Harvey M. Friedman · 2020 · PLoS Pathogens
21. Nucleoside-Modified mRNA Vaccines Protect IFNAR –/– Mice against Crimean-Congo Hemorrhagic Fever Virus Infection
    Sofia Appelberg, Lijo John, Norbert Pardi, Ákos Végvári, Sándor Bereczky, Gustaf Ahlén, Vanessa Monteil, Samir Abdurahman, Flora Mikaeloff, Mitchell Beattie et al. · 2021 · Journal of Virology
22. Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters
    Michael K. Lo, Jessica R. Spengler, Stephen R. Welch, Jessica R. Harmon, JoAnn D. Coleman-McCray, Florine E. M. Scholte, Punya Shrivastava-Ranjan, Joel M. Montgomery, Stuart T. Nichol, Drew Weissman et al. · 2019 · The Journal of Infectious Diseases
23. Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets
    Young‐Il Kim, Do-Kyun Kim, Kwang-Min Yu, Hogyu David Seo, Shin-Ae Lee, Mark Anthony B. Casel, Seung‐Gyu Jang, Stephanie Kim, WooRam Jung, Chih‐Jen Lai et al. · 2021 · mBio
24. Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
    Serge Goldman, D Bron, Thomas Tousseyn, Irina Vierasu, Laurent Dewispelaere, Pierre Heimann, Elie Cogan, Michel Goldman · 2021 · Frontiers in Medicine
25. mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
    Laura Matarazzo, Paulo J. G. Bettencourt · 2023 · Frontiers in Immunology
26. An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses
    Feifei Xiong, Chi Zhang, Baoyuan Shang, Mei Zheng, Qi Wang, Yahong Ding, Jian Luo, Xiuling Li · 2023 · Emerging Microbes & Infections
27. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization
    Cody S. Nelson, Jennifer Anne Jenks, Norbert Pardi, Matthew L. Goodwin, Hunter K. Roark, Whitney Edwards, Jason S. McLellan, Justin Pollara, Drew Weissman, Sallie R. Permar · 2020 · Journal of Virology
28. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
    Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagné, Lilin Lai, Juan I. Moliva, Barbara J. Flynn, Angela Choi, Matthew Koch, Kathryn E. Foulds et al. · 2021 · Nature Immunology
29. Enhancing Vaccine Efficacy and Stability: A Review of the Utilization of Nanoparticles in mRNA Vaccines
    Nargish Parvin, Sang Woo Joo, Tapas Kumar Mandal · 2024 · Biomolecules
30. Development and applications of mRNA treatment based on lipid nanoparticles
    Zhe Wang, Wanting Ma, Xingxing Fu, Yanfei Qi, Yinan Zhao, Shubiao Zhang · 2023 · Biotechnology Advances
31. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
    Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, Henri Estanbouli, Aurélie Bouteau, Botond Z. Igyártó · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
32. Messenger RNA-Based Vaccines Against Infectious Diseases
    Alameh, Mohamad-Gabriel, Weissman, Drew, Pardi, Norbert · 2020 · Current Topics in Microbiology and Immunology
33. COVID-19: Insights into Potential Vaccines
    Ke-Yan Loo, Vengadesh Letchumanan, Hooi‐Leng Ser, Siew Li Teoh, Jodi Woan‐Fei Law, Loh Teng‐Hern Tan, Nurul‐Syakima Ab Mutalib, Kok‐Gan Chan, Learn−Han Lee · 2021 · Microorganisms
34. mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
    Clifford T. H. Hayashi, Yi Cao, Leor C. Clark, Abhai K. Tripathi, Fidel P. Zavala, Garima Dwivedi, James J. Knox, Mohamad‐Gabriel Alameh, Paulo J.C. Lin, Ying K. Tam et al. · 2022 · npj Vaccines
35. A review of HSV pathogenesis, vaccine development, and advanced applications
    Lan Bai, Jiuzhi Xu, Linghui Zeng, Long Zhang, Fangfang Zhou · 2024 · Molecular Biomedicine
36. Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines
    Maria L. Guevara, Stefano Persano, Francesca Persano · 2019 · Current Pharmaceutical Design
37. Self-amplifying mRNA vaccines: Mode of action, design, development and optimization
    Mohammad Mostafa Pourseif, Yosef Masoudi‐Sobhanzadeh, Erfan Azari, Sepideh Parvizpour, Jaleh Barar, Rais Ahmad Ansari, Yadollah Omidi · 2022 · Drug Discovery Today
38. Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination
    István Tombácz, Drew Weissman, Norbert Pardi · 2020 · Methods in molecular biology
39. Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice
    Willis, Elinor, Pardi, Norbert, Parkhouse, Kaela, Mui, Barbara L., Tam, Ying K., Weissman, Drew, Hensley, Scott E. · 2020 · Science Translational Medicine
40. An Overview of the Use of Nanoparticles in Vaccine Development
    Daniel Lozano, Vicente Larraga, María Vallet‐Regí, Miguel Manzano · 2023 · Nanomaterials
41. mRNA vaccine designs for optimal adjuvanticity and delivery
    Yuki Mochida, Satoshi Uchida · 2024 · RNA Biology
42. mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo
    Qiannan Cao, Huapan Fang, Huayu Tian · 2024 · Biomaterials
43. Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses
    Zachary R. Stromberg, Will Fischer, Steven B. Bradfute, Jessica Z. Kubicek-Sutherland, Peter Hraber · 2020 · Vaccines
44. Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors
    Carolyn M. Nielsen, Ane Ogbe, Isabela Pedroza‐Pacheco, Susanne E. Doeleman, Yue Chen, Sarah E. Silk, Jordan R. Barrett, Sean C. Elias, Kazutoyo Miura, Ababacar Diouf et al. · 2021 · Cell Reports Medicine
45. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
    Lorenzo Canti, Stéphanie Humblet‐Baron, Isabelle Desombere, Julika Neumann, Pieter Pannus, Leo Heyndríckx, Aurélie Henry, Sophie Servais, Évelyne Willems, Grégory Ehx et al. · 2021 · Journal of Hematology & Oncology
46. Vaccine adjuvants for infectious disease in the clinic
    Morgan J. Goetz, Naaz Thotathil, Zongmin Zhao, Samir Mitragotri · 2024 · Bioengineering & Translational Medicine
47. Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity
    Saed Abbasi, Miki Matsui-Masai, Fumihiko Yasui, Akimasa Hayashi, Theofilus A. Tockary, Yuki Mochida, Shiro Akinaga, Michinori Kohara, Kazunori Kataoka, Satoshi Uchida · 2024 · Molecular Therapy
48. An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application
    Dan Su, Han Li-ping, Chengyu Shi, Yujia Li, Shaoju Qian, Zhiwei Feng, Lili Yu · 2024 · Virulence
49. B Cell Response to Vaccination
    Wei Luo, Qian Yin · 2021 · Immunological Investigations
50. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development
    Jie Liang, Xiao Zhao · 2021 · Cancer Biology and Medicine
51. Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape
    André E. Nel, Jeff F. Miller · 2021 · ACS Nano
52. An Update on mRNA-Based Viral Vaccines
    Subbiah Jeeva, Ki‐Hye Kim, Chong Hyun Shin, Bao‐Zhong Wang, Sang‐Moo Kang · 2021 · Vaccines
53. Current Vaccine Platforms in Enhancing T-Cell Response
    Takehiro Ura, Masaki Takeuchi, Tatsukata Kawagoe, Nobuhisa Mizuki, Kenji Okuda, Masaru Shimada · 2022 · Vaccines
54. mRNA vaccines in the prevention and treatment of diseases
    Yangzhuo Gu, Jiangyao Duan, Na Yang, Yuxin Yang, Xing Zhao · 2022 · MedComm
55. mRNA Vaccine Protects against Zika Virus
    Lex G. Medina-Magües, Janina Gergen, Edith Jasny, Benjamin Petsch, Jaime Lopera-Madrid, Emily S. Medina-Magües, Cristhian Salas-Quinchucua, Jorge E. Osorio · 2021 · Vaccines
56. Advances in the design and delivery of RNA vaccines for infectious diseases
    Abhijeet Girish Lokras, Thomas Rønnemoes Bobak, Saahil Sandeep Baghel, Federica Sebastiani, Camilla Foged · 2024 · Advanced Drug Delivery Reviews
57. Lipid Nanoparticle-Associated Inflammation is Triggered by Sensing of Endosomal Damage: Engineering Endosomal Escape Without Side Effects
    Serena Omo‐Lamai, Yufei Wang, Manthan N. Patel, Eno‐Obong Essien, Mengwen Shen, Aparajeeta Majumdar, Carolann L. Espy, Jichuan Wu, Breana Channer, Michael P. Tobin et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
58. Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses
    Fredrika Hellgren, Alberto Cagigi, Rodrigo Arcoverde Cerveira, Sebastian Ols, Theresa Kern, Ang Lin, Bengt Eriksson, Michael Dodds, Edith Jasny, Kim Schwendt et al. · 2023 · Nature Communications
59. An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections
    Divya Sharma, Supriya Sharma, Natasha Akojwar, Ayusha Dondulkar, Nikhil Y. Yenorkar, Deepti Pandita, Satyendra Kuldip Prasad, Mahaveer Dhobi · 2023 · Vaccines
60. Immune Correlate-Guided HIV Vaccine Design
    Galit Alter, Dan H. Barouch · 2018 · Cell Host & Microbe
61. Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans
    Shannon R. Christensen, Sushila A. Toulmin, Trevor Griesman, Lois E. Lamerato, Joshua G. Petrie, Emily Toth Martin, Arnold S. Monto, Scott E. Hensley · 2019 · Journal of Virology
62. Nanoparticles in clinical trials of COVID-19: An update
    Abdur Rauf, Tareq Abu‐Izneid, Anees Ahmed Khalil, Nabia Hafeez, Ahmed Olatunde, Md. Mominur Rahman, Prabhakar Semwal, Yahya Saleh Al-Awthan, Omar Salem Bahattab, Ishaq Nasib Khan et al. · 2022 · International Journal of Surgery
63. Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates
    Corbett, Kizzmekia S., Nason, Martha C., Flach, Britta, Gagne, Matthew, O’ Connell, Sarah, Johnston, Timothy S., Shah, Shruti N., Edara, Venkata Viswanadh, Floyd, Katharine, Lai, Lilin et al. · 2021
64. mRNA Vaccines against Flaviviruses
    Wollner, Clayton J., Richner, Justin M. · 2021 · Vaccines
65. New-onset IgA nephropathy following COVID-19 vaccination
    Yaohui Ma, Gaosi Xu · 2022 · QJM
66. The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice
    Wanyue Zhang, Annabelle Pfeifle, Casey Lansdell, Grant E. Frahm, Jonathon Cecillon, Levi A. Tamming, Caroline Gravel, Jun Gao, Sathya N. Thulasi Raman, Lisheng Wang et al. · 2023 · Vaccines
67. Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern
    Ankita Saha, Sounak Ghosh Roy, Richa Dwivedi, Prajna Tripathi, Kamal Kumar, Shashank Manohar Nambiar, Rajiv Pathak · 2025 · Vaccines
68. Folate Receptor α-Modified Nanoparticles for Targeting of the Central Nervous System
    Kuplennik, Nataliya, Lang, Kristina, Steinfeld, Robert, Sosnik, Alejandro · 2019 · ACS Applied Materials & Interfaces
69. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
    Yuxiang Zhao, Linchuan Gan, Dangjin Ke, Qi Chen, Yajuan Fu · 2023 · Journal of Translational Medicine
70. Gene delivery for immunoengineering
    Sarah Y. Neshat, Stephany Y. Tzeng, Jordan J. Green · 2020 · Current Opinion in Biotechnology
71. Strategies for induction of HIV‐1 envelope‐reactive broadly neutralizing antibodies
    Wilton B. Williams, Kevin J. Wiehe, Kevin O. Saunders, Barton F. Haynes · 2021 · Journal of the International AIDS Society
72. The Development of mRNA Vaccines for Infectious Diseases: Recent Updates
    Nitika, Jiao Wei, Ai‐Min Hui · 2021 · Infection and Drug Resistance
73. SARS-CoV-2 variants: biology, pathogenicity, immunity and control
    Ryuta Uraki, Bette Korber, Michael Diamond, Yoshihiro Kawaoka · 2025 · Nature Reviews Microbiology
74. An mRNA vaccine to prevent genital herpes
    Sita Awasthi, Harvey M. Friedman · 2021 · Translational research
75. The potential of mRNA vaccines in cancer nanomedicine and immunotherapy
    Shulin Pan, Rangrang Fan, Bo Ram Han, Aiping Tong, Gang Feng Guo · 2023 · Trends in Immunology
76. Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
    Lucas J. Kerstetter, Stephen Buckley, Carly M. Bliss, Lynda Coughlan · 2021 · Frontiers in Immunology
77. SARS-CoV-2 vaccines in patients with SLE
    Wei Tang, Anca Askanase, Leila Khalili, Joan T. Merrill · 2021 · Lupus Science & Medicine
78. Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
    LaTourette, Philip C., Awasthi, Sita, Desmond, Angela, Pardi, Norbert, Cohen, Gary H., Weissman, Drew, Friedman, Harvey M. · 2020 · Vaccine
79. Polymer-Coated Gold Nanospheres Do Not Impair the Innate Immune Function of Human B Lymphocytes in Vitro
    Sandra Hočevar, Ana M. Milosevic, Laura Rodríguez‐Lorenzo, Liliane Ackermann-Hirschi, Inès Mottas, Alke Petri‐Fink, Barbara Rothen‐Rutishauser, Carole Bourquin, Martin J. D. Clift · 2019 · ACS Nano
80. cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice
    Wandi S. Zhu, Lai Wei, Chunhong Dong, Ye Wang, Joo Hee Kim, Yao Ma, Gilbert X. Gonzalez, Bao‐Zhong Wang · 2022 · Molecular Therapy — Nucleic Acids
81. saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern
    Mai Komori, Takuto Nogimori, Amber L. Morey, Takashi Sekida, Keiko Ishimoto, Matthew R. Hassett, Yuji Masuta, Hirotaka Ode, Tomokazu Tamura, Rigel Suzuki et al. · 2023 · Nature Communications
82. Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion
    Zhen Qin, Aurélie Bouteau, Christopher Herbst, Botond Z. Igyártó · 2022 · PLoS Pathogens
83. From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics
    Tetiana Korzun, Abraham S. Moses, Parham Diba, Ariana L. Sattler, Olena R. Taratula, Gaurav Sahay, Oleh Taratula, Daniel L. Marks · 2023 · Pharmaceuticals
84. Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
    Nicholas M. Provine, Paul Klenerman · 2022 · European Journal of Immunology
85. Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity
    Tapas Patra, Keith Meyer, Yuki Haga, Erin K. Reagan, Drew Weissman, Ranjit Ray · 2023 · npj Vaccines
86. Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses
    Sonia Ndeupen, Aurélie Bouteau, Christopher Herbst, Zhen Qin, Sonya Jacobsen, Nicholas E. Powers, Zachary Hutchins, Drishya Kurup, Leila Zabihi Diba, Megan Watson et al. · 2022 · PLoS Pathogens
87. An overview of lipid constituents in lipid nanoparticle mRNA delivery systems
    Shiqi Wu, Lixin Lin, Lu Shi, Shuai Liu · 2024 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
88. Vaccines to prevent genital herpes
    Kevin P. Egan, Lauren M. Hook, Philip LaTourette, Angela Desmond, Sita Awasthi, Harvey M. Friedman · 2020 · Translational research
89. Effects of mRNA Modifications on Translation: An Overview
    Bijoyita Roy · 2021 · Methods in molecular biology
90. A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax
    Nawapol Kunkeaw, Wang Nguitragool, Eizo Takashima, Niwat Kangwanrangsan, Hiromi Muramatsu, Mayumi Tachibana, Tomoko Ishino, Paulo J.C. Lin, Ying K. Tam, Sathit Pichyangkul et al. · 2023 · npj Vaccines
91. In Gratitude for mRNA Vaccines
    Lynda M. Stuart · 2021 · New England Journal of Medicine
92. The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections
    Hong You, Malcolm K. Jones, Catherine A. Gordon, Alexa E. Arganda, Pengfei Cai, Harry Al-Wassiti, Colin William Pouton, Donald Peter McManus · 2023 · Clinical Microbiology Reviews
93. Immune imprinting: The persisting influence of the first antigenic encounter with rapidly evolving viruses
    Mariam Maltseva, Alexa Keeshan, Curtis Cooper, Marc‐André Langlois · 2024 · Human Vaccines & Immunotherapeutics
94. Promising Adjuvants and Platforms for Influenza Vaccine Development
    Wandi Zhu, Chunhong Dong, Lai Wei, Bao‐Zhong Wang · 2021 · Pharmaceutics
95. Targeting the hallmarks of aging to improve influenza vaccine responses in older adults
    Andreia N. Cadar, Dominique E. Martin, Jenna M. Bartley · 2023 · Immunity & Ageing
96. Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans
    Fredrika Hellgren, Anja Rosdahl, Rodrigo Arcoverde Cerveira, Klara Lenart, Sebastian Ols, Yong-Dae Gwon, Seta Kurt, Anna Maria Delis, Gustav Joas, Magnus Evander et al. · 2024 · JCI Insight
97. An mRNA lipid nanoparticle-incorporated nanofiber-hydrogel composite for cancer immunotherapy
    Yining Zhu, Zhi‐Cheng Yao, Shuyi Li, Jingyao Ma, Christine Y. Wei, Di Yu, Jessica L. Stelzel, Bobby Y. X. Ni, Yang Miao, Kyra Van Batavia et al. · 2025 · Nature Communications
98. Innovations in HIV-1 Vaccine Design
    Letitia D. Jones, Michael Anthony Moody, Amelia B. Thompson · 2020 · Clinical Therapeutics
99. Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan
    Keiichi Matsuzaki, Ryousuke Aoki, Yoshihito Nihei, Hitoshi Suzuki, Masao Kihara, Takashi Yokoo, Naoki Kashihara, Ichiei Narita, Yusuke Suzuki · 2021 · Clinical and Experimental Nephrology
100. mRNA vaccines induce rapid antibody responses in mice
     Makda S. Gebre, Susanne Rauch, Nicole Roth, Janina Gergen, Jingyou Yu, Xiaowen Liu, Andrew C. Cole, Stefan O. Mueller, Benjamin Petsch, Dan H. Barouch · 2022 · npj Vaccines